Cytokinetics Inc financial data

Symbol
CYTK on Nasdaq
Industry
Pharmaceutical Preparations
Location
350 Oyster Point Boulevard, ., South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 830 % -4.13%
Debt-to-equity -768 % -87.7%
Return On Equity 335 % +76.4%
Return On Assets -50.2 % +18.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 118M shares +20.4%
Common Stock, Shares, Outstanding 102M shares +7.18%
Entity Public Float 2B USD 0%
Common Stock, Value, Issued 118K USD +25.5%
Weighted Average Number of Shares Outstanding, Basic 118K shares +22.5%
Weighted Average Number of Shares Outstanding, Diluted 118K shares +22.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.22M USD -58.8%
Research and Development Expense 331M USD +3.31%
General and Administrative Expense 197M USD +7.43%
Operating Income (Loss) -525M USD -5.81%
Nonoperating Income (Expense) 44.1M USD +69.9%
Net Income (Loss) Attributable to Parent -576M USD -9.43%
Earnings Per Share, Basic -5.38 USD/shares +3.93%
Earnings Per Share, Diluted -5.38 USD/shares +3.93%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 46.9M USD -53%
Cash, Cash Equivalents, and Short-term Investments 1.3B USD +134%
Accounts Receivable, after Allowance for Credit Loss, Current 244K USD -90.2%
Assets, Current 1.02B USD +81.4%
Property, Plant and Equipment, Net 64.2M USD -15.1%
Operating Lease, Right-of-Use Asset 76.3M USD -4.49%
Other Assets, Noncurrent 7.73M USD -5.64%
Assets 1.44B USD +93.9%
Accounts Payable, Current 11.6M USD -16.1%
Employee-related Liabilities, Current 27.9M USD +24.7%
Accrued Liabilities, Current 49.8M USD +51.2%
Liabilities, Current 110M USD +41.3%
Operating Lease, Liability, Noncurrent 115M USD -6.11%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 1.45B USD +22.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 5.39M USD
Retained Earnings (Accumulated Deficit) -2.55B USD -29.2%
Stockholders' Equity Attributable to Parent -13.9M USD +96.8%
Liabilities and Equity 1.44B USD +93.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -130M USD -5.91%
Net Cash Provided by (Used in) Financing Activities 104M USD
Net Cash Provided by (Used in) Investing Activities 32.6M USD -80.3%
Common Stock, Shares Authorized 163M shares 0%
Common Stock, Shares, Issued 102M shares +7.18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.95M USD -80.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 113M USD +68.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 10.2M USD +25415%
Deferred Tax Assets, Valuation Allowance 573M USD +29%
Deferred Tax Assets, Gross 597M USD +27%
Operating Lease, Liability 138M USD -1.01%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -570M USD -9.21%
Lessee, Operating Lease, Liability, to be Paid 210M USD -6.03%
Property, Plant and Equipment, Gross 97.1M USD -0.46%
Operating Lease, Liability, Current 18.9M USD +9.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 19.6M USD +4.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 18.7M USD +39.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 71.4M USD -14.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 20.2M USD +3.15%
Deferred Tax Assets, Operating Loss Carryforwards 232M USD +14.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 25.2M USD +37.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 20.5M USD +1.66%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.33M USD +26.1%
Share-based Payment Arrangement, Expense 91.1M USD +37.9%
Interest Expense 35.9M USD +27.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%